Idiopathic Pulmonary Fibrosis and cannabis or cbd oil as treatment- advice or help?
My mother was diagnosed with idiopathic pulmonary fibrosis several years ago. She was actually diagnosed while I was in college, but I knew nothing about it until I graduated. She told me that she didn’t tell me anything because she wanted be to focus on my studies so that I could the degree I worked so hard to earn. She suffered in silence.
She’s had the disease for about six years (which is already 1 year over the average life expectancy of 3 to 5 years). She is currently on oxygen now (past 2 years) 24/7. She is in alot of pain all the time. She has trouble breathing and being motivated about anything at all. She is a fighter though, and she fights to make it through another day every day. I recently started researching cannabis, medical marijuana and cbd oil as alternative treatments to things like pirifidone (this drug helps with the lungs but it tends to have very negative gastrointestinal effects) or a lung transplant which she is already to old to receive. she is 65). She has alot of things she wants to do in life that she hasn’t been able to. It’s like she’s had to put her life on hold and let it deteriorate. It really breaks my heart seeing her like this because I don’t know what else to do. I help her as much as I can, but when she has those cough attacks that leave her out of breathe, it kills me. My depression and anxiety have worsened over these years (I should honestly be on antidepressants, but I went down that route before and I almost took my own life. so I don’t want them again. ). But anyway, to the point:
I was wondering if anyone in the forums with lung conditions of any kind, be it IPF or COPD. or any interstitial lung disease. anything. If you have any advice, anecdotes, or valuable info to share, please help me help my mother. I cannot keep seeing her like this. and she deserves a better quality of life for the rest of the life she has. She’s my best friend. This is such an awful disease.
The Potential Use of Cannabis in Tissue Fibrosis
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fibrosis is a condition characterized by thickening or/and scarring of various tissues. Fibrosis may develop in almost all tissues and organs, and it may be one of the leading causes of morbidity and mortality. It provokes excessive scarring that excels the usual wound healing response to trauma in numerous organs. Currently, very little can be done to prevent tissue fibrosis, and it is almost impossible to reverse it. Anti-inflammatory and immunosuppressive drugs are among the few treatments that may be efficient in preventing fibrosis. Numerous publications suggest that cannabinoids and extracts of Cannabis sativa have potent anti-inflammatory and anti-fibrogenic properties. In this review, we describe the types and mechanisms of fibrosis in various tissues and discuss various strategies for prevention and dealing with tissue fibrosis. We further introduce cannabinoids and their potential for the prevention and treatment of fibrosis, and therefore for extending healthy lifespan.
Fibrosis is a pathology associated with the replacement of parenchyma with connective tissue during the healing process. Fibrosis is defined as an excessive growth, stiffness, and sometimes scarring of different tissues or organs along with an imputed overaccumulation of extracellular matrix (ECM) components and collagen (Liu, 2011). Fibrotic illness is not well understood, it has a poor outcome and is mainly untreatable, all of which is compared to the terminal stage of cancer (Wernig et al., 2017). This condition is a lifelong pathological anomaly that may occur in various organs ( Table 1 ), with a higher frequency in the skin, liver, heart, kidneys, and lungs.
Main types of fibrosis.
|Organ/tissue||Type of fibrosis||References|
|Rabello et al. (2014)
Allanore et al. (2015)
|Hinderer and Schenke-Layland (2019)
Ho et al. (2010)
Khan and Sheppard (2006)
Chronic myelogenous leukemia
|Zahr et al. (2016)
Hinderer and Schenke-Layland (2019)
|Retroperitoneum||Retroperitoneal fibrosis||Vaglio and Maritati (2016)|
Inflammatory bowel disease
|Hinderer and Schenke-Layland (2019)|
|Joint||Arthrofibrosis||Usher et al. (2019)|
|Brain and nervous system||Glial scar
|Hinderer and Schenke-Layland (2019)|
Khaw et al. (2020)
|Lung||Idiopathic pulmonary fibrosis
|Barratt et al. (2018)
Smith et al. (2013)
Farghaly and El-Abdin (2015)
|Mediastinum||Mediastinal fibrosis||Rajput et al. (2000)|
|Klöppel et al. (2004)
Madácsy et al. (2018)
Apte et al. (2011)
Nephrogenic systemic fibrosis
Chronic kidney disease
Yahiaoui et al. (2009)
Waikhom and Taraphder (2011)
Panizo et al. (2021)
Xiao and Liu (2013)
Different types of fibrosis have been recognized based on anatomical location such as pulmonary [idiopathic pulmonary fibrosis (IPF), cystic fibrosis, emphysema], liver (cirrhosis, portal hypertension, hepatocellular carcinoma) or skin (keloids, systemic sclerosis). The most well-known and studied example of fibrosis is IPF. This condition is a lifelong, incurable illness targeting lungs. This disease usually affects middle-aged people and older adults and is characterized by a long-lasting cough along with difficulties in breathing of an unknown origin; besides IPF is very difficult to diagnose. Many IPF patients struggle with an acute worsening of breathing that is correlated with high mortality. The progression rate of this condition is very unpredictable. Some patients can deteriorate very quickly, while others may remain asymptomatic for many years. There is no generally approved treatment for this disease. The development of treatments is focused on fibroproliferation and fibrogenesis (Liu, 2011; Fujimoto et al., 2015; Hoyer et al., 2019). Because of insensitivity to pharmacological treatments, an average survival time is 3 years.
Epidemiological data on fibrosis in different organs is well documented in the literature. For example, an incidence of IPF varies between 0.6 and 17.4 per 100,000 population per year (Ley and Collard, 2013), two third of all patients were 60 years and above, and the highest prevalence was reported among patients of 80 years and above – 165.9 per 100,000 population (Raimundo et al., 2016). In Caucasians, cystic fibrosis occurs roughly in 1 in 3,000–4,000 births; and among other races, cystic fibrosis is less frequent, 1 in 4,000–10,000 in Latin Americans and 1 in 15,000–20,000 in African Americans, and even less in Asian Americans (Sanders and Fink, 2016). As to liver cirrhosis, according to 2017 data, 112 million compensated cases were reported worldwide (Sepanlou, 2020), and in patient who were more than 65 years old, a risk of severe liver fibrosis was 3.78 times higher (Kim et al., 2015). Also, more than 100 million cases of keloid are reported annually worldwide (Gauglitz et al., 2011; Li et al., 2017).
There is generally no good treatment of fibrosis and complete recovery is nearly impossible. Treatment includes various anti-inflammatory and anti-fibrotic agents with various degree of success. In this respect, cannabinoids and Cannabis sativa extracts, known for their strong anti-inflammatory potential, may be serve as useful additives to treatment of fibrosis. In this review, we will cover the pathology of fibrosis and current therapy of fibrosis as well as introduce basic components of endocannabinoid system (ECS) and propose potential use of cannabinoids for treatment of fibrosis.
Phases of Normal Wound Healing and Fibrosis
In most cases, fibrosis occurs after acute or more often chronic damage to tissues, followed by abnormal repair. There are two ways of repair of the injured tissues. The first one is the regeneration by the propagation of undamaged cells of parenchyma and the maturation of stem cells – normal wound healing process. The second one is scar tissue formation through the accumulation of connective tissues – tissue fibrosis. The regeneration is a possibility of damaged tissues to be repaired and their defective elements to be restored. Cells that remain undamaged are able to proliferate and maintain the structure of the tissue. In some cases, fibrosis may occur due to a critical tissue injury or as a result of the inability of injured tissue to accomplish the repair. Fibrosis occurs due to either a large amount of collagen deposition associated with the long-lasting inflammation or ischemic necrosis. Cell proliferation is handled by growth factors, although the central role is played by ECM and maturation of stem cells (Occleston et al., 2010).
Different types of cells, such as fibroblasts, vascular endothelial cells, and some fragments of injured tissues proliferate along with the repair of damaged tissues. In fibrosis and scarring, tissue repair is characterized by the proliferation of connective tissues rather than parenchymal tissues that happens upon normal regeneration (Galliot et al., 2017).
Phases of Wound Healing
Wound healing consists of four main phases, including hemostasis, inflammation, proliferation or granulation and remodeling or maturation, each phase lasting from days to months ( Figure 1 ).
Phases of wound healing. Phase 1, hemostasis is the process of clot formation to stop bleeding, and includes steps such as vasoconstriction, aggregation of platelets and migration of leukocytes. Phase 2, inflammation is the process of cleaning the wound and preparing for the formation of new blood vessels. It includes processes such as release of antibacterial molecules by neutrophils, engulfing of pathogens and debris by macrophages, and release of angiogenic substances to stimulation angiogenesis and granulation. Phase 3, proliferation (or granulation) – the process allowing to bring the wound edges together and seal it. It includes proliferation of the wound by fibroblasts, with secretion of glycoproteins and collagen, followed by migration of epithelial cells from the wound edges and formulation of granulation tissues. Phase 4, remodeling (or maturation) phase is mostly a continuation of proliferation phase resulting in formation of proper tissue.
Abnormal wound healing resulting in scar formation also includes similar phases/steps, such as inflammation, cell proliferation, and remodeling, but is characterized by more extensive deposition of collagen, fibrin, fibronectin, etc. (Profyris et al., 2012).
The First Phase – Hemostasis
The most crucial step is not to restore a tissue but to stop bleeding from the injured place. Coagulation starts exactly after trauma and finishes within hours. Collagen assists this process in the damaged area. Hemostasis consists of two subphases, primary and secondary hemostasis. Primary hemostasis is the formation of a plug at the injured place where endothelial cells become exposed. In the secondary hemostasis, there are two main pathways of blood clotting: the extrinsic and the intrinsic pathways, and they come together in the common pathway. The extrinsic pathway is a primary stage in plasma mediated secondary hemostasis. Due to tissue damage, tissue factor (TF also known as platelet tissue factor or factor III) is released in the plasma, which results in binding of factor VIIa and calcium to boost the activation of factor X to Xa ( Figure 2 ). The intrinsic pathway includes factors I (fibrinogen), II (prothrombin), IX (Christmas factor), X (Stuart–Prower factor), XI (Plasma thromboplastin), and XII (Hageman factor) (Robertson and Miller, 2018). The common pathway includes steps from the activation of factor X to the formation of active thrombin which brakes fibrin into a cross-linked complex.
A clot formation cascade. There are three steps of the clotting (coagulation) cascade: the intrinsic pathway (factors XII, XI, IX, and VIII), the extrinsic pathway (factor VII), and the common pathway. During clotting, cascade factor X may be activated by the extrinsic and intrinsic pathways. The common pathway consist of steps from the activation of factor X to the clot formation. Factors that are activated are shown with a lowercase “a”.
The Second Phase – Inflammation
Inflammation plays a central role in normal wound healing and fibrosis. Tissue repair and regeneration also depend on the extent of injury and inflammation. When the injury is extensive in the presence of chronic inflammation, repair may predominate even when the damaged cells can regenerate.
In normal circumstances, the inflammatory microenvironment quickly handles the damaged particles or pathogens. The essential factors of inflammation and fibrogenesis are summarized below ( Table 2 ; Newton and Dixit, 2012; Kendall and Feghali-Bostwick, 2014).
Key mediators of inflammation and fibrogenesis.
|Profibrotic factors acting on fibroblasts||TGFβ||White blood cells||Transformation of resident (subcutaneous, pulmonary, etc.) fibroblasts to myofibroblasts.
Stimulation of collagen and fibronectin transcription.
Stimulation of resting monocytes and inhibition of activated macrophages.
|IL-1β||Fibroblasts, macrophages||Inflammation promotion and fibrotic responses (in part, through activation of TNFα).||Lopez-Castejon and Brough (2011)|
|IL-6||T cells, skeletal muscle cells, macrophages||Regulation of inflammation (pro- and anti-inflammatory).
Stimulation of cellular differentiation and fibrosis.
|Tanaka et al. (2014)|
|IL-13||Mast cells, T lymphocytes, eosinophils and basophils||Stimulation of TGFβ production, proliferation of fibroblasts, collagen and MMP production.||Marone et al. (2019)|
|IL-33||Smooth muscle cells, epithelial and endothelial cells||Signals through ST2 to initiate and enhances profibrogenic cytokine production in a macrophage-dependent manner.||Li et al. (2014)|
|TNFα||Macrophages, T lymphocytes, NK cells, mast cells, eosinophils||Stimulation of inflammation and fibrosis, in part through TGF-β signaling pathway, activation of myofibroblasts and increased secretion of MMPs.||Yoshimatsu et al. (2020)|
|FGFs||Various parenchymal cells||Fibrosis enhancement through binding and activation of fibroblast growth factor receptor (FGFR).||Xie et al. (2020)|
|PDGF||Platelets, smooth muscle cells, endothelial cells and macrophages||Stimulation differentiation, proliferation, and ECM production via interaction with PDGFα and PDGFβ receptors on myofibroblasts.||Klinkhammer et al. (2018)|
|Leukotrienes (LTB4, LTC4, LTD4, LTE4)||White blood cells||Stimulation of fibroblasts proliferation and production of the matrix via modulation of the production of cyclic AMP by interaction with G-protein adenylate cyclase.||Kowal-Bielecka et al. (2007)|
|Profibrotic factors released from fibroblasts||VEGF||Macrophages, fibroblasts, platelets||Angiogenesis promotion.
Facilitates monocyte recruitment and infiltration of fibrotic tissues mediated through a VEGF-dependent sinusoidal permeability, leading either to resolution or promotion of fibrosis.
|Yang et al. (2014)|
|IL-1||Fibroblasts||Facilitates inflammation and fibrosis through autocrine stimulation of IL-1 receptor.||Kelly et al. (2019)|
|IL-6||Fibroblasts||Facilitation of inflammation and fibrosis through binding of IL-6 to IL-6Rα receptor, which then associates with the signal-transducing gp130 protein to facilitate phosphorylation of the transcription factor STAT-3. Phosphorylated STAT-3 regulates expression of pro-fibrotic genes.||Kobayashi et al. (2015)|
|IL-33||Dermal and cardiac fibroblasts||Promotion of inflammation and fibrosis by signaling through ST2 and activating TGFβ production.||Kotsiou et al. (2018)|
|Angiotensin II||Macrophages and myofibroblasts||Promotion of TGFβ mediated heart remodeling. Fibrosis enhancement via the angiotensin type 1 receptor (AT1).||Rosenkranz (2004)|
|IGFII||Fibroblasts||Stimulation of fibrosis through mannose-6-phosphate/insulin-like growth factor receptor (M6P/IGFII receptor) in turn activating latent transforming growth factor β (L-TGF-β).||Ghahary et al. (2000)|
|IGFBP-3||Fibrosis initiation and enhancement by binding IGF-I and ECM components, inducing the production of extracellular matrix components such as collagen type I and fibronectin. Inhibit IGF mediated proliferation (via MEK/ERK and PI3K/AKT).||Pilewski et al. (2005)|
|IGFBP-5||Yasuoka et al. (2009)|
|Antifibrotic factors acting on fibroblasts||PGE2||Almost all nucleated cells||Inhibition of fibroblast proliferation and suppression of collagen production. Promotion of normal fibroblast apoptosis through EP2/EP4 signaling and a reduction in the Akt activity.||Huang et al. (2009)|
|HGF||Fibroblast||Prevents fibrosis and induces tissue repair acting through Met receptor and supporting the growth in epithelial and endothelial cells, but not in myofibroblasts.||Panganiban and Day (2011)|
|PPAR ligands||Expressed in almost all tissues||Potent antifibrotic effects, reduction of β-catenin levels. Regulate the fate determination of mesenchymal cell lineage.||Jeon et al. (2017)
Vallée et al. (2017)
The Third Phase – Proliferation and Granulation
Cell proliferation is an essential component of tissue repair, wound healing and fibrogenesis. There are several types of cells, such as epithelial cells, endothelial cells, and fibroblasts that participate in fibrogenesis and normal process of healing of the wound.
Mesothelial cells originate from the embryonic mesoderm and play an essential role during trauma or infection. For instance, in pleural injuries, they assist in transporting white cells. Also, as a result of mesothelial-to-mesenchymal transition (MMT), these cells, might be genetically reprogrammed after the influence of specific stimuli. In a recent mouse model, the lineage analysis of stem cells demonstrated that MMT increased the proliferation of myofibroblasts and hepatic satellite cells during liver fibrogenesis (Tirado and Koss, 2018).
Fibrocytes are of a mesenchymal origin and are phenotypically inactive due to a low amount of rough endoplasmic reticulum. These cells produce fibroblastic components such as collagen, fibronectin, and vimentin. When influenced by TGF-β, they can produce alpha-smooth muscle actin (α-SMA) which plays a role in angiogenesis and immunity. Fibrocytes can also migrate to the damaged area with blood flow (de Oliveira and Wilson, 2020).
Fibroblasts originate from the embryonic mesoderm tissues. Due to the chemotaxis feature, fibroblasts are able to migrate within tissue in response to chemical stimuli. In case of injury, they can cause contraction of the matrix that leads to the sealing of the open wound. Fibroblasts play an important role in fibrogenesis, for example, TGF-β1 dependent differentiation into myofibroblasts (Weiskirchen et al., 2019).
Epithelial cells are located in different areas of the body, such as skin, urinary tract, blood vessels, and internal organs. One of the critical features is their ability to differentiate into different types of cells. During epithelial-to-mesenchymal transition (EMT), epithelial cells become transited cells that become sensitive to the fibroblast’s specific protein (FSP1). The plasticity of epithelial cells allows them to become a source of myofibroblasts in the damaged cells (Macara et al., 2014).
Endothelial cells are mainly responsible for the formation of a barrier in the endothelium of capillaries, venules, vein, arterioles, and arteries. Being stimulated by TGF-β, endothelial cells can release α-SMA and become able to convert into mesenchymal cells (endothelial-to-mesenchymal-transition, EndMT). It was demonstrated that EndMT could lead to fibrosis in the organs such as heart, kidney, and lungs (Sakai and Tager, 2013).
Pericytes are fibroblast-like cells that surround endothelial cells in blood vessels. Pericytes are able to contract and consequently control blood flow. In the case study, it was suggested that this type of cells produce α–SMA, neural/glial antigen (NG2) and platelet-derived growth factor receptor-β (PDGFR-β). Moreover, they are a source of myofibroblasts in pulmonary tissues. Another study reported that Foxd1 progenitor-derived pericytes prominently lead to the lung fibrosis (Sakai and Tager, 2013).
Vascular smooth muscle cells are responsible for the relaxation and contraction of blood vessels. As a result of the injury, they produce α–SMA, vimentin, desmin, and other compounds. It has also been shown that collagen type I is induced by bradykinin secretion in vascular smooth muscle cells through the TGF-β1 activation (Liu et al., 2017).
There are two main processes involved in proliferation phase of repair: formation of granulation tissues and wound contraction. Wound contraction usually starts on day 2–3 and is finished within 2 weeks. The primary cells that are responsible for this process are myofibroblasts, the unique cells that have features of fibroblasts and smooth muscle. The main role of these cells is the contraction of the wound by up to 80%. Granulation tissue is soft in touch and has a pink color. Granulation is a sign of tissue repair; it is formed by three steps: the inflammatory phase, the clearance phase, and the ingrowth of granulation tissue ( Figure 3 ). During the inflammation phase, cells that are predominantly involved in the process are monocytes and neutrophils. The clearance phase is characterized by the release of autolytic enzymes from dying cells as well as enzymes from neutrophils; macrophages also clear necrotic debris. The final phase is the ingrowth of granulation tissue during which granulation tissue is formed. This phase can be divided into two processes: angiogenesis and fibrogenesis (Baum and Duffy, 2011; Bochaton-Piallat et al., 2016; Alhajj et al., 2020).
Phases of proliferation and granulation.
Angiogenesis (neovascularization) is the development of blood vessels. Angiogenesis could be the result of sprouting either from pre-existing blood vessels or from stem cells. There are a few steps in the angiogenesis from pre-existing blood vessels. The first one involves vessel dilation that is mediated by NO, and the second step includes an increased vascular permeability that is mediated by the vascular endothelial growth factor (VEGF). The next step is a breakdown of the basement membrane and the formation of a vessel sprout. The other step is the migration of endothelial cells toward chemotactic and angiogenic stimuli that cause a proliferation of endothelial cells and their maturation leading to capillary tube remodeling. The final phase of angiogenesis is the accumulation of periendothelial cells (pericyte) (Papetti and Herman, 2002).
Angiogenesis from stem cells develops from endothelial precursor cells (EPC) stored in the bone marrow, and if needed, they migrate to the place of injury (Aldair and Montani, 2010).
The Fourth Phase – Healthy Remodeling or Remodeling With Fibrogenesis
Remodeling (maturation phase) after injury usually takes place from several weeks to months or years and depends on what type of tissue is damaged, injury location, and the associated comorbidities (infections, arteriosclerosis, vein thrombosis, nutritional status, diabetes, and some drugs). During remodeling phase, rate of synthesis of collagen by fibroblasts exceeds the rate at which it is degraded, resulting in continuous increase in the amount of collagen. Remodeling includes three steps: functional recovery, wound contraction and an increased tensile strength of the wound (Cañedo-Dorantes and Cañedo-Ayala, 2019). The maturation phase is characterized by the formation of scar tissue as well as by the absence of inflammatory cells (neutrophils, macrophages) and the termination of blood vessel proliferation. Granulation tissue in the scar is replaced by dense collagen. The scar initially consists of a provisional matrix that contains fibrin, fibronectin, and collagen type III, but later on, collagen type III is replaced by collagen type I (Reinke and Sorg, 2012). The next step is wound contraction, with the main goal being a reduction of a gap between two cut margins. Myofibroblasts play a key role during this phase. Figure 4 shows all major processes of differentiation, activation or transition of various cells into myofibroblasts. Collagen type I is responsible for the last step – an increase in the strength of the wound. The recovery of ∼80% of the original tissue strength will usually take up to 3 months.
Myofibroblast origin in fibrosis. Resident fibroblasts, pericytes, circulating progenitor cells (CD34 + , CD45 + , bone marrow–derived mesenchymal stem cells (MSC) transition, mesothelial cells undergoing mesothelial-to-mesenchymal transition (MMT), epithelial cells undergoing epithelial to mesenchymal transition (EMT) and endothelial cells undergoing endothelial-mesenchymal transdifferentiation (EndMT) are all known sources of myofibroblasts in various fibrotic diseases. ECM, extracellular matrix; TGF-β, transforming growth factor-β.
Skin wound healing can be subdivided into primary and secondary unions (Alhajj et al., 2020). By primary union (first intention), regeneration occurs with a minimum scaring tissue, for example, a clean surgical wound. By secondary union (secondary intention), the wound has the larger tissue defects with a wide distance between edges; wound healing by secondary intention occurs by regeneration and scarring. In some cases, due to abnormal wound healing, keloids or hypertrophic scars might occur. In a hypertrophic scar, there is a build-up of extra collagen fibers, which results in the elevation of the scar. Fibrillar collagen fibers are located parallel to the epidermis with a lumpy red scar, and they do not extend beyond the original scarring area. Usually, hypertrophic scars affect younger individuals with the delayed healing of wounds caused by underlying conditions such as infections, and usually, there is an improvement with the treatment. Morphologically keloids are characterized as eosinophilic, focally fragmented complexes of haphazardly arranged collagen. Also, in comparison with hypertrophic scars, one-third of keloids have α–SMA- expressing myofibroblasts. The scar tissue in keloids grows beyond the inflammation area, and it is difficult to treat (Moshref et al., 2010).
Physiological Injury Healing vs. Pathological Fibrosis
Fibrosis of the organ tissues is caused by parenchymal cell destruction (alteration or injury phase); as a result of tissue trauma, macrophages become active and enter the damaged area. Also, local immune cells create chemokines and cytokines which activate mesenchymal cells located close to the injury area. The next step is the initiation of the production of ECM and the elevated manufacturing of pro-inflammatory cytokines and angiogenic factors (Weiskirchen et al., 2019). After trauma, cells produce inflammatory mediators that provoke the anti-fibrinolytic coagulation cascade, the first step of which is the coagulation. During this stage, known as inflammation stage, platelets are activated and form fibrin clots. Next, platelets liberate inflammatory chemokines. Then the infiltration of leukocytes happens into the injured site, and they excrete profibrotic cytokines (TGF-β and IL-13). Neutrophils are typically engaged in the infiltration process earlier than lymphocytes and macrophages (Rosales, 2018).
The proliferation stage follows the inflammation stage; during this stage, fibroblasts become active, and myofibroblasts induce and deposit ECM that will be a framework through the tissue regeneration action. The last step is remodeling (Gonzalez et al., 2016). In physiological recovery, the extra volume of ECM is degraded, myofibroblasts and fibroblasts go through apoptosis, and inflammatory cells leave the recovered tissues. On the other hand, the fibrosis process extends inflammation, and myofibroblasts stimulate the elevated accumulation of ECM which leads to the creation of a perpetual fibrotic scar. The contrasting features that distinguish fibrosis from normal wound healing are chronic inflammation, the persistence of myofibroblast activity, MMP-TIMP imbalance, and the excessive ECM deposition. These differences are very important to be understood from the therapeutic point of view because drugs can be prescribed to target these particular molecular disturbances.
Fibroblasts control synthesis and catabolism of collagen as well as an increase in collagen amount by MMPs and their inhibitors (tissue inhibitors of TIMPs). Changing the balance between these mechanisms will cause the elevation or dropping of collagen amount inside the injured area. In addition, an increasing number of mesenchymal cells will aggravate response. During the remodeling phase, fibroblasts synthesize collagen at a higher rate than they degrade it, leading to the continuous accumulation of collagen. Generally, inflammation stimulates fibrosis. According to some reports, however, fibrosis is not always driven by inflammation. This fact clarifies the shortage of efficacy of anti-inflammatory mediators in the management of the fibrotic disease (Wynn, 2007; Kryczka and Boncela, 2015).
Fibrosis Prevention and Treatment Options
Prevention strategies for the development of fibrosis are very important in the modern world because life expectancy and the patients’ quality of life are expected to rise gradually. When patients are aware of avoidable risk factors for this condition, they, for example, should quit smoking to prevent the development of pulmonary fibrosis and should treat all acute diseases in time to prevent the development of chronic conditions. There are unavoidable factors such as genetics, the existing comorbidities (diabetes mellitus, herpes virus infection), the environmental exposures, air pollution as well as chronic use of some medications that also have to be considered (Zaman and Lee, 2018).
Anti-inflammatory drugs are widely used to manage fibrosis due to a strong connection between inflammation and fibrosis (Suthahar et al., 2017; Lands and Stanojevic, 2019; Simon et al., 2019). As a result of better understanding of the pathology of fibrosis, molecular targets of this condition and modern drugs affecting it have been recently discovered. A single-component medication is characterized by the presence of a single component that can target either extracellular or intracellular factors. The main extracellular targets are MMPs, growth factors, TNF. Most of the drugs targeting intracellular factors are small molecules; they can easily translocate inside the cytoplasm compared to other large molecules, like monoclonal antibodies.
There are four categories of intracellular factors that can be targeted by anti-fibrotic medicine: nuclear receptors, enzymes, other proteins, and epigenetic factors (Li et al., 2017). The antifibrotic medications suppress kinases located in the cytoplasm, and moreover, they inhibit the translocation of transcription factors responsible for the expression of profibrotic genes.
Epigenetic regulators represent a very specific category of anti-fibrotic treatment. The main targets of epigenetic-based management of fibrosis are microRNAs (miRNAs). Anti-miRs – are miRNA oligonucleotides that are able to complementary bind to miRNAs involved in fibrosis and neutralize them when deposited inside the cell. miRNAs like let-7, miR-21, miR-29, miR-155 play an important role in fibrosis, particularly in TGF-β control. Let-7 and miR-29 are antifibrotic; in contrast, miR-21 and miR-155 are profibrotic, and their expression will rise during the fibrosis. On the other hand, the decreased expression of miR-29 in systemic sclerosis (SSc) fibroblasts leads to the increased levels of type I and III collagen. The reduction of miR-29 was noted in the fibrotic reaction in the lungs, heart, and kidneys. IL-4, TGF-β, and PDGF-B reduced the level of miR-29 in SSc fibroblasts as well as in the bleomycin-induced model of skin fibrosis (Maurer et al., 2010; Harmanci et al., 2017). According to another study, miR-21 was highly elevated in animal and human models of transplant kidney nephropathy. MiR-21 –/– mice experienced less interstitial fibrosis in response to kidney injury; this was pheno-copied in wild-type mice that were treated with anti-miR-21 oligonucleotides. The peroxisome proliferator-activated receptors (Pparα) and Mpv17l are two main metabolic pathways that are key targets for miR-21. Also, miR-21 down-regulated inhibitors of angiogenesis and migration, especially the RECK (the reversion-inducing cysteine-rich protein with Kazal motifs) and the atypical matrix metalloproteinase (MMP) inhibitor that led to the enhanced MMP activity in kidney injury (Chau et al., 2012). As a result of the administration of oligonucleotides that silenced miR-21, a reversal of the deleterious action of miR-21 in kidney injury was noted. Some studies demonstrated a significant effect of miR-21 on pulmonary and cardiac fibrosis (Thum et al., 2008).
In multi-component therapy, several approaches are combined, with numerous ingredients acting on numerous targets. In fibrosis, there are multiple pathological pathways and multi-component drugs that are able to modulate these pathways and create synergistic effects. In the Table 3 , single and multi-component medications used nowadays in the treatment of fibrosis are summarized (Li et al., 2017).
Single- and multi-component medications targeting fibrosis factors.
|Group||Target or mechanism type||Mechanism of action||Drug name||Disease||Reference/trial identifier|
|Single-component medications targeting extracellular factors|
|Growth factor||Extracellular TGF-β signaling||TGF-β, inhibitor||Pirfenidone||IPF||Margaritopoulos et al. (2016)|
|PDGF/VEGF||PDGFR, antagonist||Imatinib||SSc, nephrogenic systemic fibrosis, IPF|| > NCT00677092
|VEGFR/PDGFR, antagonist||Nintedanib||Scleroderma, IPF|| > NCT02597933
|TNF||TNF, inhibitor||Talidomide||IPF||> NCT00162760|
|TNF, inhibitor||Etanercept||IPF||> NCT00063869|
|TNF, inhibitor||Belimumab||SSc||> NCT01670565|
|Cytokines||Interleukin||IL-1R1, antagonist||Anakinra||Cystic fibrosis||Iannitti et al. (2016)|
|IL-1 βR, antagonist||Rilonacept||SSc||> NCT01538719|
|Interferon||IFN-γR, stimulant||Actimmune||IPF, cystic fibrosis, liver fibrosis|| > NCT00047658
|MMP/TIMP||MMP/TIMP||MMP/TIMP, inhibitor||Marimastat||Liver fibrosis||de Meijer et al. (2010)|
|Other proteins and peptides||Endothelin||ET-1 receptor, antagonist||Macitentan||IPF||> NCT00903331|
|Bosentan||IPF|| > NCT00070590
|Ambrisentan||IPF, SSc|| > NCT00879229
|Angiotensin II||AT1 receptor, antagonist||Losartan||Cystic fibrosis, Liver fibrosis|| > NCT00298714
|GPCR||Prostacyclin receptor, agonist||Iloprost||SSc||> NCT00109681|
|Treprostinil||IPF, SSc|| > NCT00703339
|Single-component medications targeting intracellular factors|
|Enzymes||mTOR||mTORC1/2, inhibitor||Rapamycin (Sirolimus)||Renal intestinal fibrosis||> NCT01079143|
|JAK-STAT||JAK1/JAK2, inhibitor||Ruxolitinib||Myelofibrosis||> NCT00952289|
|PI3K-Akt||Akt, inhibitor||Omipalisib||IPF||> NCT01725139|
|MAPK||MAPK, inhibitor||MMI-0100||IPF, cardiac fibrosis||Xu et al. (2014)|
|NF-kB||IKK, inhibitor||IMD-1041||Cardiac fibrosis||Tanaka et al. (2012)|
|Nuclear receptors||PPAR||PPAR-γ, agonist||Rosiglitazone||Liver fibrosis||> NCT00492700|
|Other proteins||Intracellular TGF-β signaling||SMAD2/3, inhibitor||Pirfenidone||IPF, SSc|| > NCT00287729
|SMAD3/4, inhibitor||Pentoxifylline||Skin fibrosis||> NCT00001437|
|Renal fibrosis, liver fibrosis|| > NCT00686881
Meng et al. (2015)
|Epigenetics||miRNA||miR-21, inhibitor||Anti-miR-21||IPF, renal fibrosis||Liu et al. (2010)
Chau et al. (2012)
|TGF-pc/MMP-2c||Fuzhenghuayu capsule (FZHY)||Liver fibrosis|| > NCT00854087
|TNF-α/TGF-β||Danggui-Buxue-Tang (DBTG)||IPF||Lv et al. (2012)|
TGF-β, transforming growth factor-β; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; TNF, tumor necrosis factor; IFN-γR, interferon-γ receptor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; ET-1 receptor, endothelin-1 receptor; AT1 receptor, angiotensin II receptor type 1; GPCR, G protein-coupled receptor; mTOR, mechanistic target of rapamycin; mTORC1, mechanistic target of rapamycin complex 1; JAK-STAT, janus kinase/signal transducers and activators of transcriptions; PI3K-Akt, phosphoinositide 3-kinase/protein kinase B; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor kappa-light –chain- enhancer of activated B cells; IKK, I-kappa B kinase; SMAD3, mothers against decapentaplegic homolog 3.
Only nintedanib and pirfenidone have been approved by FDA for the treatment of fibrosis, particularly of IPF, and ruxolitinib has been approved by FDA for the treatment of myelofibrosis; other medications are still experimental, and some of them are undergoing clinical trials the results of which might help improve the understanding of the fibrosis pathway.
Nintedanib medication is a small molecule kinase inhibitor that reduces the proliferation and migration of lung fibroblasts. Nintedanib inhibits receptor tyrosine kinases (RTKs), for instance, FGFR1-3, VEGFR1-3, Fns-like tyrosine kinase-3 (FLT3), PDGFR α and β. Also, this drug inhibits kinase signaling pathways. Its main side effects are nausea, diarrhea, and liver dysfunction (Wind et al., 2019; Valenzuela et al., 2020). In clinical practice, a long-term use of nintedanib is still discussed. Research in this area will help improve patient outcomes (Valenzuela et al., 2020). Pirfenidone treatment mainly reduces fibroblast proliferation and causes the inhibition of collagen synthesis and down-regulation of profibrotic cytokines. As a result of inhibition, it causes the suppression of TGF-β2 mRNA levels and TGF-β2 protein and the suppressed expression of the TGF-β pro-protein convertase furin. Also, this drug decreases the MMP-11 protein levels. It should be noted that pirfenidone has some severe side effects such as photosensitivity, nausea, stomach pain and many others that may lead to medication intolerance and discontinuation (Hughes et al., 2016; Margaritopoulos et al., 2016; Moran-Mendoza et al., 2019). Ruxolitinib is widely used in myelofibrosis treatment. This drug is a kinase inhibitor that is selective for JAK1 and 2. The main role of these kinases is the regulation of growth factor signaling and cytokine release. The known side effects of this medicine are anemia, thrombocytopenia, increased liver enzymes, and diarrhea (Elli et al., 2019).
The Role of Cannabinoids and Cannabis in Inflammation and Fibrosis
Recently, the ECS has received a significant attention from mainstream medical professionals, being viewed as an important therapeutic target for many pathological conditions. Human physiology significantly depends on a proper function of this system. The ECS has been established as an important homeostatic regulator. It affects almost all functions of the body. It consists of endocannabinoids (2-AG, AEA), their metabolic enzymes and receptors, including cannabinoid receptors 1 (CB1), cannabinoid 2 (CB2), transient receptor potential channels of the vanilloid subtype 1 and 2 (TRPV1, TRPV2), G protein-coupled receptors 18, 55, 119 (GPR18, GPR55, GPR119) (Laezza et al., 2020). Cannabinoid receptors are highly expressed in cells involved in two subtypes of immunity, adaptive and innate. For example, CB1 and CB2 receptors are expressed in the natural killer cells, macrophages, T and B cells (Chiurchiù, 2016). In general, activation of the CB2 receptor leads to anti-inflammatory effects. Since the expression of CB1 receptors is lower in the immune cells than the expression of CB2 receptors, their function in the immune system still remains controversial (Turcotte et al., 2016). CB2 –/– mice exhibit abnormalities in the development of T and B cells (Ziring et al., 2006). Cannabinoids, mainly by modulating the expression of ECS receptors induce apoptosis of immune cells, and inhibit their proliferation; suppress pro-inflammatory cytokines production, and induce T-regulatory cells (Nagarkatti et al., 2009). The imbalance in the ECS can significantly impact the proper functioning of the whole organism, including fibrosis and inflammation processes. For example, the activation of the CB1 receptor leads to fibrogenesis, while the enhancement of the CB2 receptor inhibits fibrosis progression (Mallat et al., 2011). In animal models, it was demonstrated that the deletion of CB1 caused an improvement of liver fibrosis, whereas CB2 deletion resulted in an elevated amount of collagen accumulation and an increased inflammation (Patsenker and Stickel, 2016). Concerning inflammation, the use of CB2 receptor agonists was documented to inhibit the infiltration of inflammatory cells into liver tissue. In addition, CB2 receptor knockout mice had the more profound inflammation and damage to the liver than wild-type mice (Batkai et al., 2007).
Cannabis is widely known as a plant with psychoactive properties. It includes over 500 compounds such as different cannabinoids, terpenes, terpenoids, fatty acids, and flavonoids. Cannabinoids (known as phytocannabinoids in contrast to endocannabinoids) act via the ECS. The most abundant are cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC); they are the most studied cannabinoids with numerous documented medicinal properties (Zurier and Burstein, 2016; Lafaye et al., 2017). The uniqueness of the effect of cannabis extracts is in entourage effect. Often, but not always, cannabis extracts have more profound effects on various disease and conditions than isolated cannabinoids (Kovalchuk and Kovalchuk, 2020). This is due to modifying effects of minor cannabinoids, terpenes and other molecules that frequently act as amplifiers, acting on the same receptors. Looking at the enormous varieties of cannabis cultivars nowadays, it is clear that research in this field should continue to discover new possibilities of fibrosis treatment (Russo, 2019).
Cannabinoids as Anti-inflammatory Agents
According to previous reports, some of the cannabinoids can be used as anti-inflammatory agents (Zurier and Burstein, 2016; Wang et al., 2020). Currently in medical practice, these substances have little documented negative effect on patients in comparison with other drugs. Cannabinoids have other mechanisms of action on inflammation in comparison with nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs inhibit the activity of cyclooxygenase enzymes, prostaglandins (Zurier and Burstein, 2016). Recently, it has been discovered that cannabinoid receptor signaling regulates the proliferation and function of fibroblasts which are crucial cells in scar formation (Nagarkatti et al., 2009). By suppressing inflammation, they may stop the progression of repair by scarring. It has been shown that cannabinoids and cannabis extracts suppress the pro-inflammatory cytokines IL-2, IL-1β, TNF-α, IFN-γ, IL-12, IL-8, IL-6 in different cell lines and animal models. Due to this, the inflammatory process will be prominently inhibited (Nagarkatti et al., 2009).
One of the anti-inflammatory mechanisms of cannabinoids is through the regulation of mitochondrial homeostasis. CBD has been shown to alleviate cerebral ischemia in rats by reducing brain oedema, blood-brain barrier permeability, infarction size, and neurological deficit. This effect was due to the increased expression of Na + /Ca 2+ exchanger proteins (Khaksar and Bigdeli, 2017). When blood flow is restored in the ischemic area, it causes inflammation and oxidative-stress-related injury in the affected area. CBD has demonstrated a neuroprotective effect in oxygen–glucose-deprivation/reperfusion in vitro model by reducing the oxidative stress, improving mitochondrial bioenergetics and modulating the glucose metabolism (Sun et al., 2017). In contrast, THC treatment of the trophoblast cell line, HTR8/SVneo, showed a reduction in mitochondrial respiratory function and membrane potential. This data suggested that THC can cause dysfunction of mitochondria (Walker et al., 2021). When THC effect was evaluated on mitochondria, extracted from the rat brain, similar results were obtained: it enhanced oxidative stress and induced mitochondrial dysfunction in the brain (Wolff et al., 2015).
Cannabis extracts were even proposed to be used for prevention and treatment of COVID-19. Significant inhibitory effects on the key receptor protein Ace2 required for SARS-Cov2 virus entry in the gateway entry tissues was found in response to several cannabis extracts (Wang et al., 2020). Similarly, several other extracts were found to be potent inhibitors of major pro-inflammatory molecules responsible for severe COVID-19 progression (Wang et al., 2020).
It was also shown that cannabis users living with HIV have lower neuroinflammation. This was confirmed by demonstrating that marijuana users had lower levels of CD16+ monocytes and inducible protein 10 (IP-10) compared to HIV-infected patients non-cannabis users (Rizzo et al., 2018).
Cannabinoids as Anti-fibrotic Agents
A lot of research has already been done, and currently many studies are undergoing on the use of endo-, synthetic, and phytocannabinoids in the fibrosis field. In one in vivo study where a mouse model of type I cardiomyopathy was used, it was demonstrated that CBD treatment diminished the diabetes-associated cardiac fibrosis. A significant decrease of collagen deposition and the expression of profibrotic genes like MMP-2, MMP-9, TGF-β, connective tissue growth factor, fibronectin andcollagen-1 were noted (Montecucco and Di Marzo, 2012).
Liver fibrosis is a usual complication of many long-lasting liver illnesses such as viral hepatitis B and C, non-alcoholic steatohepatitis, drug-induced liver injury, alcohol abuse, and autoimmune conditions. In long-lasting liver damage, the activated hepatic stellate cells (HSCs) and myofibroblasts are the main contributors to the development of liver cirrhosis and hepatocellular cancer (Fu et al., 2011). An in vitro study performed on HSCs documented that CBD induced the programmed cell death of these cells (Lim et al., 2011). This effect was independent of cannabinoid receptors and was the result of endoplasmic reticulum stress induction. In addition, CBD enhanced the pro-apoptotic pathway IRE1/ASK1/c-Jun N-terminal kinase, which resulted in HSCs death. This CBD-induced programmed cell death of activated HSCs was confirmed in vitro in human, mouse and rat cell lines, but not in the quiescent cell lines. The well-known fact that the activated HSCs play a crucial role in the development and continuation of liver fibrosis supports the fact that cannabis extracts might be turned into promising antifibrotic drugs as they lead to the selective apoptosis of activated HSCs. The results of this study are very encouraging for further investigation of CBD in vivo (Lim et al., 2011). In addition, a meta-analysis of nine studies performed on 5,976,026 patients concluded that marijuana did not elevate the prevalence or progression of liver fibrosis in patients with hepatitis C or hepatitis C HIV co-infection (Hosein Mohimani et al., 2017). Also, it was noted that marijuana users had a reduced prevalence of non-alcoholic fatty liver disease (NAFLD). Furthermore, these patients consumed more sodas and alcohol, therefore the healthy lifestyle was not a cause of the reduced prevalence of NAFLD. This effect might be induced by reducing fat depositions via omega-3 fatty acids and the impact of CBD on insulin sensitivity (Hosein Mohimani et al., 2017).
Concerning the effect of THC, it has been shown that it also inhibits the proliferation of liver myofibroblasts and stellate cells via CB2 receptors and leads to their programmed cell death. Due to this, THC may also possess antifibrotic properties (Tam et al., 2011).
The endocannabinoid AEA also demonstrated the anti-fibrogenic features by suppressing the proliferation of HSC and induction of necrosis. The elevated AEA levels were documented in cirrhotic patients, which might be a response to fibrosis. This endogenous cannabinoid can trigger the topical inflammatory response and systemic dilatation of vessels, therefore the opportunity for fibrosis treatment was restricted (Parfieniuk and Flisiak, 2008). Another endocannabinoid, 2-AG, was considered as a fibrogenic agent. When used in higher doses in vitro on HSC, it activated fibrosis via the membrane cholesterol-dependent mechanism (Tam et al., 2011). Another endogenous cannabinoid, oleoylethanolamide (OEA), was used in a mouse model of hepatic fibrosis and showed the inhibition of collagen deposition and suppression of collagen type I and III gene expression, α-SMA, MMP2, MMP9, and TIMP1. These effects were mediated through the PPARα mechanisms (McVicker and Bennett, 2017).
Synthetic cannabinoids were also shown to be beneficial for fibrosis treatment. An in vitro study performed on pulmonary fibroblasts demonstrated that JWH133, a CB2 receptor agonist, suppressed the collagen type I and α-SMA and inhibited the proliferation and migration of fibroblasts. These effects were reversed by the use of a CB2 receptor antagonist, SR144528. In vivo studies on bleomycin-induced lung fibrosis in mice, showed that JWH133 decreased the lung density, and the fibrotic score and histological results illustrated the suppression of the collagen accumulation and inflammatory response. In both models, this particular synthetic cannabinoid inhibited the crucial pathway of fibrogenesis, TGF-β1/Smad2 (Fu et al., 2017). WIN-55,212, a nonselective CB1 and CB2 receptor agonist as well as JWH133 were assessed on the mouse model of systemic sclerosis. They prevented the development of dermal and pulmonary fibrosis and inhibited the proliferation of fibroblasts. CB2 –/– mice developed a significantly enhanced skin and lung fibrosis compared with CB2 +/+ mice, indicating significant influence of the CB2 receptor on fibrosis development (Servettaz et al., 2010). Rimonabant, a CB1 receptor antagonist, was assessed on rat models of liver cirrhosis induced by carbon tetrachloride. Fibrosis was prominently suppressed by the use of this synthetic cannabinoid in rats compared with rats in the vehicle group. Rimonabant downregulated the fibrogenic (TIMP-1, TGF-β, MMP13, MMP2, MMP9, MMP1, MMP8) and inflammatory mediator (TNF-α, MCP-1) genes. In addition, Rimonabant treatment induced a prominent increase in the expression of the CB2 receptor (Giannone et al., 2012). Another study demonstrated that chronic stimulation of CB2 receptor with selective CB2 receptor agonist, JWH-133, leads to regression of fibrosis in cirrhotic rats. This selective agonist suppressed the inflammatory infiltrate, decreased fibrosis, lowered the number of activated hepatic stellate cells, and improved arterial pressure in comparison to the vehicle group. In addition, JWH-133 reduced levels of α-SMA and collagen and elevated levels of MMP-2 in the liver tissue of rats with cirrhosis in comparison with untreated rats with cirrhosis. This data provided promising results for the possibility to use selective CB2 receptor agonists as a treatment modality of hepatic fibrosis in humans (Muñoz-Luque et al., 2008). Another study tested the effect of a selective CB2 receptor agonist, AM1241, on myocardial fibrosis post-myocardial infarction in mice. The echocardiography results demonstrated that AM1241 significantly enhanced cardiac function; downregulated expression of collagen I, collagen III, TIMP-1, and plasminogen activator inhibitor (PAI)-1. When primary cardiac fibroblasts were exposed to hypoxia and serum deprivation to simulate ischemia, AM1241 was able to reduce α-SMA, collagen I and collagen III; this effect was partially abrogated by the Nrf2 siRNA transfection. Moreover, the CB2 receptor agonist, AM1241, activated and enhanced the translocation of Nrf2 to the nucleus and inhibited the TGF-β1/SMAd3 pathway. These data suggest that activation of the CB2 receptor might be one of the key targets to combat heart fibrosis after myocardial infarction (Li et al., 2016). The chronic peripheral pharmaceutical blockage of CB1 receptor (by SLV319 or JD5037 selective CB1 receptor antagonists) or genetic inactivation of CB1 receptors in the renal proximal tubule cells reduced kidney inflammation, suppressed tubulointerstitial fibrosis, and diminished diabetic-induced changes in the kidneys in mice. Also, the downregulation of the CB1 receptor suppressed glucose transporter 2, which resulted in reduced glucose reabsorption. These data supported the fact that peripheral CB1 receptor antagonists might be useful in treating patients with diabetic nephropathy (Hinden et al., 2018). A synthetic analog of THC, ajulemic acid (lenabasum), being a CB2 agonist, significantly prevented the development of bleomycin-induced skin fibrosis in mice and suppressed its progression. In addition, it inhibited collagen synthesis by skin fibroblasts obtained from patients with scleroderma. These effects were achieved by stimulating PPAR-γ signaling (Gonzalez et al., 2012). Lenabasum has been shown to have an anti-inflammatory capacity by directly affecting both arachidonic acid pathways (Burstein, 2021). Lenabasum was the only synthetic cannabinoid studied in human fibrotic diseases. A Phase II, randomized, placebo-controlled trial in adults suffering from systemic sclerosis showed promising results ( > NCT03398837); a high improvement rate on the immunosuppressant therapy background, and high improvement on mycophenolate that has an anti-fibrotic activity and prevents pulmonary deterioration in pulmonary fibrosis was observed. Unfortunately, the primary endpoint was not met during this trial (Spiera et al., 2021). Table 3 summarizes type of cannabinoids and their mechanism of action ( Table 4 ).